Tecartus wins NICE recommendation for mantle cell lymphoma
CAR-T therapy receives NICE backing within weeks of EMA authorisation
Read More
Tag: Mantle Cell Lymphoma
Calquence shows long-term efficacy and tolerability in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca’s Calquence remained progression free for a median of 22 months
Read More
Kite files second CAR-T therapy with US regulators
A submission in the EU is expected early next year
Read More
Final NHS nod for Janssen’s Imbruvica
Janssen’s Imbruvica will be routinely available on the NHS to treat certain patients with mantle cell lymphoma (MCL), after cost regulators issued a final green light for the drug.
Read More
NICE recommends Imbruvica for some MCL patients
It is looking likely that a subgroup of patients with mantle cell lymphoma (MCL) will get routine access to Janssen’s Imbruvica on the NHS.
Read More
FDA approves AstraZeneca’s Calquence
AstraZeneca’s Calquence has been given a speedy green light in the US as a treatment for adults with mantle cell lymphoma.
Read More
Priority review and breakthrough status for AZ’ acalabrutinib
AstraZeneca and group member Acerta Pharma say acalabrutinib is being given a priority review by the US Food and Drug Administration for mantle cell lymphoma (MCL), hot on the heels of it having been assigned a breakthrough designation by the regulator.
Read More
Celgene’s Revlimid approved for Mantle Cell Lymphoma
Celgene’s Revlimid has been approved by European regulators to treat patients with relapsed/refractory Mantle Cell Lymphoma (MCL), a rare sub-type of aggressive non-Hodgkin’s lymphoma (NHL).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
